名古屋市立大学病院は、愛知県名古屋市瑞穂区にある公立大学法人名古屋市立大学の附属大学病院。

During the past decade, Nagoya City University Hospital conducted 109 clinical trials. In the 10-year time frame, 109 clinical trials started and 37 clinical trials were completed, i.e. on average, 33.9% percent of trials that started reached the finish line to date. In the past 5 years, 73 clinical trials started and 27 clinical trials were completed. i.e. 37% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Nagoya City University Hospital" #1 sponsor was "Janssen Research & Development, LLC" with 17 trials, followed by "Pfizer" with 15 trials sponsored, "Celgene" with 12 trials sponsored, "Amgen" with 8 trials sponsored and "Hoffmann-La Roche" with 8 trials sponsored. Other sponsors include 67 different institutions and companies that sponsored additional 41 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Nagoya City University Hospital" #1 collaborator was "Eli Lilly and Company" with 4 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 2 trials as a collaborator, "Chugai Pharmaceutical" with 2 trials as a collaborator, "Daiichi Sankyo, Inc." with 2 trials as a collaborator and "Galapagos NV" with 2 trials as a collaborator. Other collaborators include 15 different institutions and companies that were collaborators in the rest 24 trials.

According to Clinical.Site data, the most researched conditions in "Nagoya City University Hospital" are "Multiple Myeloma" (26 trials), "Psoriasis" (7 trials), "Generalized Pustular Psoriasis" (5 trials), "Ulcerative Colitis" (5 trials) and "Alzheimer Disease" (3 trials). Many other conditions were trialed in "Nagoya City University Hospital" in a lesser frequency.

Most popular intervention types in "Nagoya City University Hospital" are "Drug" (118 trials), "Other" (13 trials), "Biological" (7 trials), "Procedure" (5 trials) and "Device" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (32 trials), "Dexamethasone" (15 trials), "Bortezomib" (10 trials), "Daratumumab" (10 trials) and "Lenalidomide" (8 trials). Other intervention names were less common.

The vast majority of trials in "Nagoya City University Hospital" are 124 trials for "All" genders, 5 trials for "Male" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Nagoya City University Hospital". undefined are not yet recruiting, 32 are recruiting, 34 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 54 completed trials in Nagoya City University Hospital, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Nagoya City University Hospital, 17 "Phase 1" clinical trials were conducted, 44 "Phase 2" clinical trials and 67 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 3 trials that are defined as “Not Applicable".